Frost et al. suggested that retinal amyloid-Beta tests can differentiate between the presence of AD with 100% sensitivity [107], and this association between ND diseases and early biomarkers including the amyloid-Beta, tau proteins and inflammation has been further echoed in more recent reviews [21], [22], [24], [25], [104]. The gene discussed is MAPT; the disease is Alzheimer disease.